Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Scopolamine hydrobromide injection in hyperlactatemic septic shock
ChiCTR2500097562Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Feb 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of scopolamine in septic shock (2 arms), sponsored by Ruijin Hospital. Primary endpoint: 28-day all-cause mortality. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
scopolamine
03
Conditions
septic shock
Beyond the preview
Go deeper on ChiCTR2500097562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097562.